$246 Million is the total value of RP Management, LLC's 5 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2022 |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-11
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BIOHAVEN PHARMACTL HLDG CO L | 16 | Q3 2022 | 77.6% |
VIRACTA THERAPEUTICS INC | 14 | Q2 2024 | 5.7% |
EPIZYME INC | 11 | Q2 2022 | 44.1% |
BIOCRYST PHARMACEUTICALS INC | 11 | Q2 2024 | 52.0% |
EPIZYME INC | 11 | Q2 2022 | 13.9% |
CYTOKINETICS, INC | 11 | Q2 2024 | 29.7% |
SUNESIS PHARMACEUTICALS INC | 9 | Q4 2020 | 0.1% |
IMMUNOMEDICS INC | 8 | Q3 2020 | 55.7% |
BIOHAVEN LTD | 7 | Q2 2024 | 89.2% |
View RP Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CYPRESS BIOSCIENCE INC | December 23, 2010 | 3,815,000 | 9.9% |
View RP Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-27 |
13F-HR | 2024-08-13 |
13F-HR | 2024-05-08 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
4 | 2022-08-16 |
View RP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.